Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen to Acquire Immunological Reagent Maker Caltag for $20M in Cash

NEW YORK, May 16 (GenomeWeb News) - Invitrogen will acquire Caltag Laboratories, a manufacturer of immunological reagents, for $20 million in cash, the company said today.

 

Caltag, based in Burlingame, Calif., makes antibodies and reagents for flow cytometry applications, including tandem dyes for multi-color flow cytometry. In addition to research tools, the company has developed technologies for diagnostics. Fifteen of its products are FDA-approved class II in vitro diagnostic devices. The company's German subsidiary offers more than 200 antibodies approved for diagnostic sales in the European Union.

 

Invitrogen, which acquired antibody maker Zymed Laboratories earlier this year, believes Caltag will complement its proteomics technologies. "Caltag's strength in supporting flow cytometry work is a natural fit for this goal through its synergies with Invitrogen's upstream proteomics technologies," said Cheri Walker, Invitrogen's vice president of proteomics, in a company statement.

 

Caltag's USstaff of about 50 will remain in the San Franciscoarea as part of Invitrogen's Antibody Center of Excellence. The acquisition is scheduled to close by the end of June, and Caltag is expected to have approximately $10 million in sales in the following year.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.